Neurogene Inc. Files 8-K with Financials and Reg FD Disclosure

Ticker: NGNE · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1404644

Sentiment: neutral

Topics: financial-statements, regulation-fd, corporate-update

Related Tickers: NGNE

TL;DR

Neurogene Inc. dropped an 8-K on Jan 13, 2025, with financials and Reg FD stuff. Check it out.

AI Summary

Neurogene Inc. filed an 8-K on January 13, 2025, reporting on events that occurred on the same date. The filing primarily concerns financial statements and exhibits, along with a Regulation FD Disclosure. The company, formerly known as Neoleukin Therapeutics, Inc., is based in New York, NY.

Why It Matters

This 8-K filing provides updated financial information and regulatory disclosures for Neurogene Inc., which is crucial for investors to assess the company's current financial health and compliance status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K for financial statements and exhibits, not indicating any immediate material adverse events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Neurogene Inc.?

The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits, with the earliest event reported as of January 13, 2025.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on January 13, 2025.

What is Neurogene Inc.'s principal executive office address?

Neurogene Inc.'s principal executive office is located at 535 W 24th Street, 5th Floor, New York, NY 10011.

Has Neurogene Inc. operated under any former names?

Yes, Neurogene Inc. was formerly known as Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, and AQUINOX PHARMACEUTICALS (USA) INC.

What is the SIC code for Neurogene Inc.?

The Standard Industrial Classification (SIC) code for Neurogene Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-01-13 07:30:18

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 13, 2025, Neurogene Inc. posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 attached hereto is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information or Exhibit 99.1 be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Corporate Presentation (January 2025) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NEUROGENE INC. Date: January 13, 2025 By: /s/ Christine Mikail Name: Christine Mikail Title: President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing